Table 1.

Background characteristics of the study participants (n = 37)

		Total n = 37
		Median	IQR
Age (years)		52	44–61
Body mass at baseline (kg)		53.6	49.1–58.2
Body fat mass at baseline (kg)		15.3	11.8–19.2
BMI at baseline (kg/m2)		21.7	19.2–23.3
		n	%
Disease	Right breast cancer	18	48.6
	Left breast cancer	12	32.4
	Bilateral breast cancer	7	18.9
Purpose of the treatment	Neoadjuvant	15	40.5
	Adjuvant	15	40.5
	Recurrence or advanced	7	18.9
Disease stage	I	7	18.9
	II	18	48.6
	III	5	13.5
	IV	7	18.9
Disease subtype	ER + /Her2 −	17	45.9
	ER − /Her2 +	3	8.1
	ER + /Her2 +	17	45.9
Chemotherapy regimen	T	15	40.5
	THP	17	45.9
	TCbHP	3	8.1
	TC	2	5.4
Her2 status	Her2 +	20	54.1
	Her2 −	17	45.9
Menopausal status	Pre-menopausal	18	48.6
	Post-menopausal	19	51.4
Smoker	Yes	8	21.6
	No	29	78.4
History of alcohol consumption	Yes	11	29.7
	No	26	70.3
Use of diuretics	Yes	7	18.9
	No	30	81.1
Marital status	Yes	19	51.4
	No	18	48.6
In employment	Yes	15	40.5
	No	22	59.5
Educational background	Junior high school	2	5.4
	High school	9	24.3
	College school	8	21.6
	Undergraduate or above	17	45.9
	No answer	1	2.7
Income	< 2 million yen p.a	4	10.8
	2–6 million yen p.a	13	35.1
	> 6 million yen p.a	7	18.9
	No answer	13	35.1

BMI Body mass index, ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, p.a. per annum, T Docetaxel, TC Docetaxel and cyclophosphamide, TCbHP Docetaxel, carboplatin, trastuzumab, and pertuzumab, THP Docetaxel, trastuzumab, and pertuzumab